Login to Your Account

Other news to note

Wednesday, May 7, 2014

TNI Biotech Inc., of Orlando, Fla., said it obtained approval from the Government of Malawi's drug regulatory authority, the Malawi Pharmacy, Medicines and Poisons Board, for the marketing and sale of low-dose naltrexone in Malawi for the treatment of patients with cancer. TNI said it intends to seek approval for sale in additional emerging nations.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription